Checkpoint blockade and adoptive T cell therapy are efficacious in some patients, but many do not respond to these immunotherapies. Chou et al. recently elucidated the characteristics of a new cell population with greater cytotoxicity, improved tumor homing, and reduced exhaustion compared to conventional cytotoxic T cells. These cells may improve the efficacy of cancer immunotherapies, especially for patients refractory or unresponsive to current approaches.
Keywords: T cell exhaustion; immunosurveillance; immunotherapy; innate-like cytotoxic T cells; tumor homing.
Published by Elsevier Inc.